Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

The effects of the nationwide stimulant shortage on a private psychiatry practice

Christine Tran-Boynes, DO
Meds
February 8, 2023
Share
Tweet
Share

I have a solo outpatient private practice focusing on psychiatric medication management and brief therapy for adults. Early on, I decided to accept insurance to help address the shortage of psychiatrists in this country. Because of the advances in telemedicine since the pandemic, I can see patients throughout the state where I am licensed. This should be the happiest time in my career. After several years of working as an employee for several hospitals, I can now practice medicine on my own terms. Given the abundance of out-of-network psychiatrists in my area, patients are often grateful to be seen despite the wait for an initial appointment.

However, one situation has been stressful for my patients and me: the current nationwide stimulant shortage.

Stimulants, such as Adderall, Ritalin, and Concerta, are first-line treatments for ADHD. Often considered a childhood condition, ADHD can persist into adulthood, especially with inattentive symptoms. Although not found in the DSM-5-TR criteria for ADHD, studies have shown that those with ADHD have a higher rate of debt.

Additionally, stimulants can be used to treat depression and narcolepsy.

Due to their risk of misuse, stimulants are classified as Schedule II controlled substances by the DEA. Before the declaration of a public health emergency due to COVID in January 2020, a federal law called the Ryan Haight Act mandated that an in-person medical evaluation be conducted before a controlled substance can be prescribed. However, with the public health emergency, the Ryan Haight Act has been waived, and the public health emergency was recently renewed for another 90 days on January 11, 2023.

On October 12, 2022, the FDA announced the nationwide shortage of Adderall. As psychiatrists were substituting other stimulants for Adderall, shortages of other stimulants soon followed, including Ritalin.

There are several reasons for the stimulant shortage. One, Teva, one of the largest manufacturers of Adderall, was experiencing production delays due to a worker shortage in October 2022. Additionally, the DEA imposes an annual maximum production of stimulants to avoid misuse. Lastly, there has been an increase in demand for stimulants, especially with the waiver of the Ryan Haight Act during the public health emergency and the subsequent ability to prescribe stimulants during telemedicine visits.

Sadly, the stimulant shortage is expected to last well into 2023.

How is the stimulant shortage affecting the patients in my practice? Some patients have resorted to taking their medications only on the weekdays, when they need them the most for work or school. Others call their pharmacy and are put on hold for as long as an hour, only to be told that information about stimulant supplies cannot be provided over the phone. A few have had success visiting several pharmacies in person. A couple of determined patients have traveled three hours to fill their prescriptions.

As an adult psychiatrist, I treat ADHD less frequently than my child and adolescent psychiatrist colleagues. As a result, I am less familiar with the newer, brand-name stimulants on the market. However, with the shortage, I find myself using these exact brand-name stimulants with the guidance of colleagues as well as reviewing continuing medical education material that address conversions of different stimulants. With this, I am spending more administrative time completing prior authorizations and obtaining manufacturer coupons from pharmaceutical companies. Once, I spent 90 minutes in a peer-to-peer review with an insurance company.

In the media, the opioid crisis has been at the forefront. However, I believe there is also a stimulant crisis occurring right now. There is a feeling of helplessness when I cannot provide the medications I prescribe for my patients. Although I am frustrated, it probably does not compare to how my patients are feeling. That said, the stimulant shortage has only added to the moral injury of psychiatrists throughout the country.

Christine Tran-Boynes is a psychiatrist.

Prev

The hidden toll of racism in medicine: a doctor's perspective

February 8, 2023 Kevin 0
…
Next

Navigating the gray area: a doctor's perspective on treating a colleague

February 8, 2023 Kevin 1
…

ADVERTISEMENT

Tagged as: Psychiatry

Post navigation

< Previous Post
The hidden toll of racism in medicine: a doctor's perspective
Next Post >
Navigating the gray area: a doctor's perspective on treating a colleague

ADVERTISEMENT

More by Christine Tran-Boynes, DO

  • 5 ways to manage anxiety during the coronavirus pandemic

    Christine Tran-Boynes, DO

Related Posts

  • Why the baby formula shortage happened

    Divya Srinivasan and Tejas Sekhar
  • International medical graduates ease the U.S. doctor shortage

    G. Richard Olds, MD
  • How to start reversing the clinician shortage today

    Timothy Lee, MPH
  • Medical school is more than practice problems

    Kira Kopacz
  • Why a prison psychiatry rotation should be mandatory for all medical students

    Tiana Walker
  • A shortage of Kayexalate leads to an ER visit

    Hans Duvefelt, MD

More in Meds

  • FDA delays could end vital treatment for rare disease patients

    G. van Londen, MD
  • Pharmacists are key to expanding Medicaid access to digital therapeutics

    Amanda Matter
  • How medicine repurposing enables value-based pain management and insomnia therapy

    Olumuyiwa Bamgbade, MD
  • Forced voicemail and diagnosis codes are endangering patient access to medications

    Arthur Lazarus, MD, MBA
  • From stigma to science: Rethinking the U.S. drug scheduling system

    Artin Asadipooya
  • How drugmakers manipulate your health from diagnosis to prescription

    Martha Rosenberg
  • Most Popular

  • Past Week

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • America’s ER crisis: Why the system is collapsing from within

      Kristen Cline, BSN, RN | Conditions
    • Why timing, not surgery, determines patient survival

      Michael Karch, MD | Conditions
    • How early meetings and after-hours events penalize physician-mothers

      Samira Jeimy, MD, PhD and Menaka Pai, MD | Physician
  • Past 6 Months

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • The hidden health risks in the One Big Beautiful Bill Act

      Trevor Lyford, MPH | Policy
  • Recent Posts

    • Beyond burnout: Understanding the triangle of exhaustion [PODCAST]

      The Podcast by KevinMD | Podcast
    • Facing terminal cancer as a doctor and mother

      Kelly Curtin-Hallinan, DO | Conditions
    • Online eye exams spark legal battle over health care access

      Joshua Windham, JD and Daryl James | Policy
    • FDA delays could end vital treatment for rare disease patients

      G. van Londen, MD | Meds
    • Pharmacists are key to expanding Medicaid access to digital therapeutics

      Amanda Matter | Meds
    • Why ADHD in women requires a new approach [PODCAST]

      The Podcast by KevinMD | Podcast

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

Leave a Comment

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

  • Most Popular

  • Past Week

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • America’s ER crisis: Why the system is collapsing from within

      Kristen Cline, BSN, RN | Conditions
    • Why timing, not surgery, determines patient survival

      Michael Karch, MD | Conditions
    • How early meetings and after-hours events penalize physician-mothers

      Samira Jeimy, MD, PhD and Menaka Pai, MD | Physician
  • Past 6 Months

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • The hidden health risks in the One Big Beautiful Bill Act

      Trevor Lyford, MPH | Policy
  • Recent Posts

    • Beyond burnout: Understanding the triangle of exhaustion [PODCAST]

      The Podcast by KevinMD | Podcast
    • Facing terminal cancer as a doctor and mother

      Kelly Curtin-Hallinan, DO | Conditions
    • Online eye exams spark legal battle over health care access

      Joshua Windham, JD and Daryl James | Policy
    • FDA delays could end vital treatment for rare disease patients

      G. van Londen, MD | Meds
    • Pharmacists are key to expanding Medicaid access to digital therapeutics

      Amanda Matter | Meds
    • Why ADHD in women requires a new approach [PODCAST]

      The Podcast by KevinMD | Podcast

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Leave a Comment

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...